{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:48:20Z","timestamp":1773164900115,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1124\/dmd.121.000707","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T04:15:27Z","timestamp":1645589727000},"page":"1218-1227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine"],"prefix":"10.1016","volume":"50","author":[{"given":"Antonio J.","family":"L\u00f3pez Qui\u00f1ones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Salvador","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000707_bib1","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/febs.14577","article-title":"Glucose transporters in cancer - from tumor cells to the tumor microenvironment","volume":"285","author":"Ancey","year":"2018","journal-title":"FEBS J"},{"key":"10.1124\/dmd.121.000707_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","article-title":"The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients","volume":"12","author":"Anderson","year":"1994","journal-title":"J Hypertens"},{"key":"10.1124\/dmd.121.000707_bib3","series-title":"Package insert.","year":"2018"},{"key":"10.1124\/dmd.121.000707_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nucmedbio.2016.05.013","article-title":"Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids","volume":"43","author":"Bayer","year":"2016","journal-title":"Nucl Med Biol"},{"key":"10.1124\/dmd.121.000707_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/mpo.2950150405","article-title":"Update on basic research and clinical experience with metaiodobenzylguanidine","volume":"15","author":"Beierwaltes","year":"1987","journal-title":"Med Pediatr Oncol"},{"key":"10.1124\/dmd.121.000707_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0001-2998(78)80004-X","article-title":"Adrenal imaging agents: rationale, synthesis, formulation and, metabolism","volume":"8","author":"Beierwaltes","year":"1978","journal-title":"Semin Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/1096-911X(200008)35:2<153::AID-MPO18>3.0.CO;2-7","article-title":"False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma","volume":"35","author":"Biasotti","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"10.1124\/dmd.121.000707_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/BF00256941","article-title":"Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine","volume":"15","author":"Blake","year":"1989","journal-title":"Eur J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00259-013-2510-z","article-title":"Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis","volume":"40","author":"Bleeker","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1124\/dmd.121.000707_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-020-00662-w","article-title":"Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake","volume":"10","author":"Blom","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1124\/dmd.121.000707_bib11","first-page":"3338","article-title":"Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors","volume":"9","author":"Carlin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000707_bib12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4236\/ajac.2019.1011041","article-title":"Determination of impurities and degradation products\/causes for m-iodobenzylguanidine using HPLC-tandem mass spectrometry","volume":"10","author":"Chen","year":"2019","journal-title":"Am J Analyt Chem"},{"key":"10.1124\/dmd.121.000707_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2967\/jnumed.113.124057","article-title":"Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane","volume":"55","author":"Chin","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib14","first-page":"469","article-title":"Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"Coleman","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1124\/dmd.121.000707_bib15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.neuroscience.2007.01.072","article-title":"Expression and immunolocalization of the plasma membrane monoamine transporter in the brain","volume":"146","author":"Dahlin","year":"2007","journal-title":"Neuroscience"},{"key":"10.1124\/dmd.121.000707_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ejca.2008.01.010","article-title":"Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age","volume":"44","author":"de Kraker","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.121.000707_bib17","first-page":"1452","article-title":"I-131 MIBG therapy has been used as the first line therapy in pheochromocytoma","volume":"61","author":"Dhingra","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/jpet.110.170142","article-title":"Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3","volume":"335","author":"Duan","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000707_bib19","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1074\/jbc.M112.436972","article-title":"Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene","volume":"288","author":"Duan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000707_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/250834","article-title":"Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: a report from the Children\u2019s Oncology Group","volume":"2012","author":"Dubois","year":"2012","journal-title":"Int J Mol Imaging"},{"key":"10.1124\/dmd.121.000707_bib21","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.21.00703","article-title":"Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT Consortium","volume":"39","author":"DuBois","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.121.000707_bib22","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-14-3240","article-title":"Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma","volume":"21","author":"DuBois","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000707_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00043426-199905000-00005","article-title":"Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival","volume":"21","author":"DuBois","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1124\/dmd.121.000707_bib24","series-title":"StatPearls","article-title":"Physiology, adrenal gland","author":"Dutt","year":"2021"},{"key":"10.1124\/dmd.121.000707_bib25","first-page":"6147","article-title":"Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients","volume":"47","author":"Ehninger","year":"1987","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.121.000707_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-7258(01)00144-9","article-title":"The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines","volume":"91","author":"Eisenhofer","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000707_bib27","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.121.000707_bib28","doi-asserted-by":"crossref","first-page":"50042","DOI":"10.1074\/jbc.M407913200","article-title":"Identification and characterization of a novel monoamine transporter in the human brain","volume":"279","author":"Engel","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000707_bib29","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2020"},{"key":"10.1124\/dmd.121.000707_bib30","series-title":"Radiopharmaceuticals and Labelled Compounds","article-title":"Carrier-free 11C-labeled catecholamines in nuclear medicine and biochemical research","author":"Fowler","year":"1973"},{"key":"10.1124\/dmd.121.000707_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.2910470615","article-title":"Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging","volume":"47","author":"Gaze","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1124\/dmd.121.000707_bib32","first-page":"1140","article-title":"Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters","volume":"34","author":"Glowniak","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"Gorboulev","year":"1997","journal-title":"DNA Cell Biol"},{"key":"10.1124\/dmd.121.000707_bib34","first-page":"129","article-title":"Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans","volume":"31","author":"Gordon","year":"1990","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib35","first-page":"1342","article-title":"Sympathomimetic effects of MIBG: comparison with tyramine","volume":"40","author":"Graefe","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib36","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.ajpath.2011.02.020","article-title":"Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy","volume":"178","author":"Grube","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.121.000707_bib37","doi-asserted-by":"crossref","first-page":"15850","DOI":"10.1074\/jbc.M212816200","article-title":"The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake","volume":"278","author":"H\u00f6ltje","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000707_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.121.000707_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pcl.2014.09.015","article-title":"Neuroblastoma: paradigm for precision medicine","volume":"62","author":"Irwin","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1124\/dmd.121.000707_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/pbc.23062","article-title":"Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed\/refractory neuroblastoma","volume":"57","author":"Johnson","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.121.000707_bib41","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1128\/MCB.21.16.5471-5477.2001","article-title":"Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene","volume":"21","author":"Jonker","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1124\/dmd.121.000707_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nucmedbio.2020.09.004","article-title":"[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma","volume":"90\u201391","author":"Kobayashi","year":"2020","journal-title":"Nucl Med Biol"},{"key":"10.1124\/dmd.121.000707_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tips.2004.05.005","article-title":"Polyspecific organic cation transporters: their functions and interactions with drugs","volume":"25","author":"Koepsell","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.121.000707_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","article-title":"The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics","volume":"135","author":"Kogai","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000707_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5603\/EP.a2018.0024","article-title":"131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study","volume":"69","author":"Kotecka-Blicharz","year":"2018","journal-title":"Endokrynol Pol"},{"key":"10.1124\/dmd.121.000707_bib46","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters","volume":"89","author":"K\u00f6lby","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.121.000707_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1124\/dmd.121.000707_bib48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.2910470119","article-title":"Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C)","volume":"47","author":"Lashford","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1124\/dmd.121.000707_bib49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/BF02574771","article-title":"The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma","volume":"13","author":"Lashford","year":"1988","journal-title":"Eur J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib50","doi-asserted-by":"crossref","first-page":"27055","DOI":"10.1074\/jbc.M114.570564","article-title":"Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands","volume":"289","author":"Lee","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000707_bib51","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/mol.118.112482","article-title":"Organic cation transporter 3 facilitates fetal exposure to metformin during pregnancy","volume":"94","author":"Lee","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000707_bib52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000707_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/17425255.2.4.505","article-title":"Drug-drug interactions involving membrane transporters in the human kidney","volume":"2","author":"Li","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000707_bib54","first-page":"21","article-title":"Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors","volume":"57","author":"Liu","year":"2013","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1124\/dmd.121.000707_bib55","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0002-9610(00)00296-8","article-title":"Adrenal pheochromocytoma remains a frequently overlooked diagnosis","volume":"179","author":"Lo","year":"2000","journal-title":"Am J Surg"},{"key":"10.1124\/dmd.121.000707_bib56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1124\/dmd.121.000707_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/mol.120.119495","article-title":"Characterization of meta-iodobenzylguanidine (mIBG) transport by polyspecific organic cation transporters: implication for mIBG therapy","volume":"98","author":"L\u00f3pez Qui\u00f1ones","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000707_bib58","first-page":"1088","article-title":"No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation","volume":"36","author":"Mairs","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib59","first-page":"37","article-title":"Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma","volume":"27","author":"Mangner","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib60","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000707_bib61","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2006030205","article-title":"Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2","volume":"17","author":"Masuda","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000707_bib62","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.bjc.6605621","article-title":"Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force","volume":"102","author":"Matthay","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.121.000707_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.121.000707_bib64","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.121.000707_bib65","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2006.09.3484","article-title":"Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma","volume":"25","author":"Matthay","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.121.000707_bib66","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/pbc.21391","article-title":"Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy","volume":"50","author":"Modak","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.121.000707_bib67","first-page":"4342","article-title":"Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms","volume":"51","author":"Montaldo","year":"1991","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.121.000707_bib68","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-10-2949","article-title":"Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems","volume":"17","author":"More","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000707_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","article-title":"Renal transporters in drug development","volume":"53","author":"Morrissey","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.121.000707_bib70","first-page":"672","article-title":"The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy","volume":"24","author":"Nakajo","year":"1983","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib71","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJM199311183292103","article-title":"Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease","volume":"329","author":"Neumann","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.121.000707_bib72","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00003072-199609000-00005","article-title":"Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT","volume":"21","author":"Nielsen","year":"1996","journal-title":"Clin Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib73","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2012.00194","article-title":"Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers","volume":"2","author":"Orentas","year":"2012","journal-title":"Front Oncol"},{"key":"10.1124\/dmd.121.000707_bib74","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.121.000707_bib75","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.semnuclmed.2016.02.002","article-title":"131I-metaiodobenzylguanidine theranostics in neuroblastoma: historical perspectives; practical Applications","volume":"46","author":"Parisi","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0001-2998(05)80157-6","article-title":"The biodistribution of metaiodobenzylguanidine","volume":"22","author":"Parisi","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcl.2007.10.014","article-title":"Neuroblastoma: biology, prognosis, and treatment","volume":"55","author":"Park","year":"2008","journal-title":"Pediatr Clin North Am"},{"key":"10.1124\/dmd.121.000707_bib78","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1523\/JNEUROSCI.15-09-06179.1995","article-title":"Differential expression of two vesicular monoamine transporters","volume":"15","author":"Peter","year":"1995","journal-title":"J Neurosci"},{"key":"10.1124\/dmd.121.000707_bib79","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib80","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma","volume":"104","author":"Rao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.121.000707_bib81","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0959-8049(95)00042-H","article-title":"Release mechanisms of [125I]meta-iodobenzylguanidine in neuroblastoma cells: evidence of a carrier-mediated efflux","volume":"31A","author":"Servidei","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.121.000707_bib82","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/jm00317a017","article-title":"Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine","volume":"10","author":"Short","year":"1967","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000707_bib83","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.semnuclmed.2011.06.001","article-title":"Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience","volume":"41","author":"Shusterman","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib84","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/0006-2952(90)90615-R","article-title":"Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells","volume":"39","author":"Smets","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000707_bib85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FJC.0b013e3182270783","article-title":"Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization","volume":"58","author":"Solbach","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/dmd.121.000707_bib86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.25200","article-title":"Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy","volume":"62","author":"Streby","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.121.000707_bib87","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00259-015-3179-2","article-title":"Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children\u2019s Oncology Group","volume":"43","author":"Temple","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1124\/dmd.121.000707_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrn1008","article-title":"Plasma membrane monoamine transporters: structure, regulation and function","volume":"4","author":"Torres","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/dmd.121.000707_bib89","first-page":"669","article-title":"MIBG-treatment in neuroblastoma; experiences of the T\u00fcbingen\/Frankfurt group","volume":"271","author":"Treuner","year":"1988","journal-title":"Prog Clin Biol Res"},{"key":"10.1124\/dmd.121.000707_bib90","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/cncr.10447","article-title":"High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma","volume":"94","author":"van Santen","year":"2002","journal-title":"Cancer"},{"key":"10.1124\/dmd.121.000707_bib91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/164_2021_446","article-title":"Brain plasma membrane monoamine transporter in health and disease","volume":"266","author":"Vieira","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/dmd.121.000707_bib92","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21932","article-title":"(123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial","volume":"52","author":"Vik","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.121.000707_bib93","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1523\/JNEUROSCI.16-07-02352.1996","article-title":"Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract","volume":"16","author":"Wade","year":"1996","journal-title":"J Neurosci"},{"key":"10.1124\/dmd.121.000707_bib94","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.phrs.2016.06.002","article-title":"Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics","volume":"111","author":"Wagner","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.121.000707_bib95","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.118.082131","article-title":"Disposition of methamphetamine and major metabolites in mice: role of organic cation transporter 3 in tissue-selective accumulation of para-hydroxymethamphetamine","volume":"46","author":"Wagner","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000707_bib96","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1038\/s41598-019-43880-6","article-title":"A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma","volume":"9","author":"Wakabayashi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.121.000707_bib97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/cpt.442","article-title":"The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition","volume":"100","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000707_bib98","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/03602530701690390","article-title":"The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient","volume":"39","author":"Wang","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.121.000707_bib99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/dmd.121.000707_bib100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02736730","article-title":"Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat","volume":"5","author":"Weihe","year":"1994","journal-title":"J Mol Neurosci"},{"key":"10.1124\/dmd.121.000707_bib101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/jm00368a008","article-title":"Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines","volume":"27","author":"Wieland","year":"1984","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000707_bib102","first-page":"349","article-title":"Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine","volume":"21","author":"Wieland","year":"1980","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib103","series-title":"Endotext [Internet]","article-title":"Adrenal cortex; development, anatomy, physiology","author":"Willenberg","year":"2017"},{"key":"10.1124\/dmd.121.000707_bib104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.20187","article-title":"Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry","volume":"31","author":"Wimalasena","year":"2011","journal-title":"Med Res Rev"},{"key":"10.1124\/dmd.121.000707_bib105","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.121.000707_bib106","doi-asserted-by":"crossref","first-page":"F682","DOI":"10.1152\/ajprenal.00302.2006","article-title":"Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells","volume":"292","author":"Xia","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/dmd.121.000707_bib107","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/dmd.121.000707_bib108","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","article-title":"Renal drug transporters and their significance in drug-drug interactions","volume":"6","author":"Yin","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.121.000707_bib109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.apsb.2019.12.005","article-title":"Targeting uptake transporters for cancer imaging and treatment","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.121.000707_bib110","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1124\/dmd.110.032987","article-title":"Adenosine transport by plasma membrane monoamine transporter: reinvestigation and comparison with organic cations","volume":"38","author":"Zhou","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000707_bib111","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/dmd.107.015495","article-title":"Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine","volume":"35","author":"Zhou","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:57:26Z","timestamp":1739955446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624008596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":111,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0090955624008596"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000707","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}